Supplementary Figures S1-6, Supplementary Tables S1-3, Supplementary methods from TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer

TET1, TET2 and TET3 expression in breast cancer and its association with survival. Putative TET2 and TET3 methylation targets in breast cancer. Differential gene expression analysis in TCGA triple negative breast cancer patients. Putative TET1 methylation targets in ovarian cancer. 5hmC slot blot in TET1 KD cells. Drug validation assays. RNA-seq and DREAM analyses in Hs578T cells. CRISPR gRNA sequences. List of drugs correlated with TET1 expression in breast and ovarian cancer cell lines. Supplemental methods related to RNA-seq, DREAM and bioinformatics.